Alizyme is a speciality biopharmaceutical development company, focused on the therapeutic areas of metabolic disorders, gastrointestinal disorders and cancer supportive care. It is developing cetilistat for the treatment and management of obesity and related diseases, such as type 2 diabetes, COLAL-PRED(R) for ulcerative colitis, and ATL-104 for mucositis, a side effect of cancer therapy.
Sorry, the comment form is closed at this time.